Loading…
Loading…
The Tema Heart & Health ETF (HRTS) is designed to strategically invest in companies poised to benefit from cutting-edge developments within the biotechnology and broader healthcare industries. Its investment mandate specifically targets firms focused on advancing treatments and therapies for cardiovascular health, metabolic disorders, and weight management.
Is HRTS's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.
Novo Nordisk's CagriSema delivers 25% weight loss in women, spotlighting three ETFs for diversified exposure to the sector's growth.
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since listing its first product with $5 million.1 Tema has grown AUM by more than $3 billion in the first five months of 2026,2 underscoring strong momentum and growing adoption from financial advisors and professional investors.
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.